Logo

Sarepta Entered into a Research Collaboration and Option Agreement with GenEdit to Develop Gene Editing Therapies for Neuromuscular Diseases

Share this
Sarepta Entered into a Research Collaboration and Option Agreement with GenEdit to Develop Gene Editing Therapies for Neuromuscular Diseases

Sarepta Entered into a Research Collaboration and Option Agreement with GenEdit to Develop Gene Editing Therapies for Neuromuscular Diseases

Shots:

  • GenEdit to receive ~$57M up front and is also eligible to receive future development, regulatory and commercial milestones along with royalties. Sarepta gets exclusive option rights to license polymer nanoparticles that were developed by GenEdit for 4 neuromuscular indications
  • The collaboration will combine Sarepta’s gene-editing technologies and GenEdit’s non-viral delivery platform to develop new genetic therapies for patients with neuromuscular diseases
  • Additionally, in vivo results showed the potential of GenEdit’s polymer nanoparticles to deliver therapeutic cargo at muscle tissue after systemic administration to target & non-viral systemic delivery of genetic medicines

Ref: Globe Newswire | Image: Fierce Biotech

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions